Vestergaard et al. in Japan reported an increased CCR4/TARC expression in atopic dermatitis considered as a T-helper (Th) 2-dominated disease.29 Also, Rottman et al. postulated that increased CCR4 expression in psoriasis lesions may contribute to T lymphocyte trafficking to the dermis.30 Anti-CCR4 monoclonal antibodies (mAbs) have been recently recommended for the treatment of T-cell lymphomas, asthma and patients with CCR4-positive Hodgkin’s lymphoma.9,31-34. The gene discussed is CCL17; the disease is psoriasis.